Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,137
Out of 5,090 analysts
36
Total ratings
35%
Success rate
-23.76%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $47.11 | -10.85% | 1 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Hold | $30 → $13 | $13.10 | -0.76% | 3 | Oct 14, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $485.21 | -10.97% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $5.06 | +58.10% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.67 | +124.01% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $74.74 | -55.85% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.17 | +2,284.40% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $21.55 | +25.32% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.28 | +207.02% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.12 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.85 | +549.35% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $4.42 | +338,898.37% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.37 | +472.74% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.48 | +18.74% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $340.33 | -35.36% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $181.82 | +70.50% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $122.42 | -34.65% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $47.11
Upside: -10.85%
Astria Therapeutics
Oct 14, 2025
Downgrades: Hold
Price Target: $30 → $13
Current: $13.10
Upside: -0.76%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $485.21
Upside: -10.97%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $5.06
Upside: +58.10%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.67
Upside: +124.01%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $74.74
Upside: -55.85%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.17
Upside: +2,284.40%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $21.55
Upside: +25.32%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.28
Upside: +207.02%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.12
Upside: -
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.85
Upside: +549.35%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $4.42
Upside: +338,898.37%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $4.37
Upside: +472.74%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $29.48
Upside: +18.74%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $340.33
Upside: -35.36%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $181.82
Upside: +70.50%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $122.42
Upside: -34.65%